Stocktoria
CHINA PHARMA HOLDINGS, INC. CPHI
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2000-02-15
CHINA PHARMA HOLDINGS, INC. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M | $10.9M | $12.3M | $13.2M | $15.6M |
| Gross profit | -$131,950 | -$2.0M | -$281,085 | -$493,916 | $349,270 | $2.0M | $1.5M | $2.0M | $2.5M | $3.2M |
| R&D expense | $280,901 | $283,942 | $240,080 | $185,858 | $318,964 | $377,964 | $229,637 | $172,384 | $90,474 | $365,969 |
| Operating income | -$3.2M | -$4.6M | -$2.8M | -$3.5M | -$2.9M | -$2.6M | -$20.4M | -$10.4M | -$18.7M | -$8.2M |
| Interest expense | $27,272 | $27,353 | $30,572 | $434,619 | $542,001 | $294,159 | $321,718 | $451,258 | $539,334 | $849,557 |
| Income tax | — | — | — | — | — | — | — | -$109,989 | $122,631 | $308,175 |
| Net income | -$3.2M | -$4.7M | -$3.1M | -$4.0M | -$3.4M | -$2.9M | -$20.7M | -$10.8M | -$19.3M | -$9.2M |
| EPS (diluted) | $-0.74 | $-2.71 | $-0.91 | $-3.78 | $-0.74 | — | — | — | — | — |
| Operating cash flow | $148,261 | -$406,063 | -$699,686 | -$409,545 | -$249,838 | -$42,260 | $608,312 | $1.9M | $841,216 | $2.9M |
| Free cash flow | $88,937 | -$444,474 | -$711,203 | -$811,509 | -$687,893 | -$909,567 | $472,309 | $1.8M | $704,737 | $2.7M |
| Cash & equivalents | $345,112 | $626,879 | $1.4M | $2.0M | $4.9M | $957,653 | $1.1M | $1.2M | $2.0M | $2.7M |
| Inventory | $1.6M | $2.3M | $3.7M | $2.9M | $2.9M | $3.7M | $3.6M | $5.1M | $6.4M | $7.3M |
| Total assets | $31.0M | $14.9M | $16.5M | $17.8M | $22.6M | $21.1M | $22.2M | $45.4M | $60.0M | $78.5M |
| Total liabilities | $8.3M | $7.1M | $9.0M | $13.5M | $16.6M | $13.1M | $13.0M | $15.2M | $16.9M | $19.6M |
| Shareholders' equity | $22.7M | $7.7M | $7.5M | $4.3M | $6.0M | $8.0M | $9.2M | $30.2M | $43.1M | $58.9M |
Growth · year-over-year · Revenue CAGR -13.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -8.5% | -35.4% | -13.5% | -15.9% | -11.3% | -0.5% | -11.4% | -6.7% | -15.1% | -23.5% |
| Free cash flow growth | — | — | — | — | — | -292.6% | -74.2% | +159.8% | -73.9% | -33.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001106644 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.